Results: For the intention-to-treat population, the response rate with GDP was 45
Molecular Formula C22H29FO5 Synonyms Dexamethasone (DHAP) PD062964 SW219971-1 Molecular Weight 392
Background The combination of dexamethasone, high-dose cytarabine, and cisplatin (DHAP) is an established salvage regimen for lymphoma patients
The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R-DLBCL) after second-line treatment failure is extremely poor
However, only a minority of patients achieved a PET-negative response after BV monotherapy
Cisplatin n
We hypothesized that substitution of cisplatin by oxaliplatin (L-OHP) could result in less toxicity and greater efficacy
DHAP chemotherapy induced profound mye-losuppression with marked neutropenia and thrombocytopenia (Table 6)
Such strategies have yielded response rates of 65–85% and complete The upper boundary of the one-sided 95
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i) (DHAP) reinduction regimen by addition of the oral mammalian target
CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des
Background: Non-Hodgkin's lymphomas are the eighth-most prevalent malignancy in females and the eleventh in males
The dose of dexamethasone is identical to that used in the DHAP regimen though the cisplatin dose is slightly lower
9% over 24 hours
Cytarabine (Ara-C) 2,000 mg/m 2 (IV infusion) in 500 mL sodium chloride 0
Background/aims: Data on dexamethasone, cytarabine, and cisplatin (DHAP) as a mobilization regimen, compared to high-dose cyclophosphamide (HDC), for up-front autologous stem cell transplantation (ASCT) in non-Hodgkin's lymphoma (NHL) is limited